The Oncomap™ ExTra test previously known as GEM (Genomic Enabled Medicine) ExTra® test combines the ultra-comprehensive genomic insights expected from whole exome, whole transcriptome sequencing with the actionability and accessibility of patients need to inform crucial treatment decisions. The test provides treating physicians with vital interpreted information they need to understand changes to their patient’s genomic profile, and outline an optimal therapeutic treatment plan. Conditions that may benefit from this approach include treatment of advanced, refractory, rare, or aggressive cancers.
Hematological Malignancies, Solid Tumor
EGFR (Epidermal growth factor receptor), TERT (Telomerase Reverse Transcriptase)
Next-Generation Sequencing (NGS)